The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 18, 2015

Filed:

Jul. 16, 2009
Applicants:

Jacques F. Banchereau, Montclair, NJ (US);

Gerard Zurawski, Midlothian, TX (US);

Anne-laure Flamar, Dallas, TX (US);

Amanda Cobb, Forth Worth, TX (US);

Holly Mead, Plano, TX (US);

Monica Montes, Dallas, TX (US);

Sandra Zurawski, Midlothian, TX (US);

Sangkon OH, Baltimore, MD (US);

Inventors:

Jacques F. Banchereau, Montclair, NJ (US);

Gerard Zurawski, Midlothian, TX (US);

Anne-Laure Flamar, Dallas, TX (US);

Amanda Cobb, Forth Worth, TX (US);

Holly Mead, Plano, TX (US);

Monica Montes, Dallas, TX (US);

Sandra Zurawski, Midlothian, TX (US);

SangKon Oh, Baltimore, MD (US);

Assignee:

Baylor Research Institute, Dallas, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/005 (2006.01); C07K 14/15 (2006.01); C07K 16/28 (2006.01); A61K 47/48 (2006.01); A61K 39/21 (2006.01);
U.S. Cl.
CPC ...
C07K 14/005 (2013.01); A61K 39/21 (2013.01); A61K 47/4833 (2013.01); A61K 47/48538 (2013.01); A61K 47/48561 (2013.01); C07K 14/15 (2013.01); C07K 16/2878 (2013.01); C07K 2319/01 (2013.01); C07K 2319/035 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C12N 2740/16011 (2013.01); C12N 2740/16222 (2013.01); C12N 2740/16234 (2013.01); C12N 2740/16322 (2013.01); C12N 2740/16334 (2013.01);
Abstract

The present invention includes compositions and methods for making and using a vaccine that includes a DC-specific antibody or fragment thereof to which an engineered Gag antigen is attached to form an antibody-antigen complex, wherein the Gag antigen is less susceptible to proteolytic degradation by eliminating one or more proteolytic sites or a DC-specific antibody or fragment thereof to which an engineered Nef antigen is attached to form an antibody-antigen complex, wherein the Nef antigen comprises one or more codon usage optimization that increase antibody-antigen complex secretion, or both, wherein the vaccine is able to elicit an HIV-specific T cell immune response to Gag p17, Gag p24, Nef and/or Cyclin D1.


Find Patent Forward Citations

Loading…